Menopausal symptoms in epithelial ovarian cancer survivors: a GINECO VIVROVAIRE2 study

F. Gernier, François Gernier, A Gompel, Anne Gompel, C. Rousset-Jablonski, Christine Rousset‐Jablonski, E. Kalbacher, Elsa Kalbacher, A. Floquet, Anne Floquet, D. Berton-Rigaud, Dominique Berton-Rigaud, O. Tredan, Olivier Trédan, J. Alexandre, Jérôme Alexandre, P. Follana, Philippe Follana, A. Zannetti, Alain Zannetti, N. Dohollou, Nadine Dohollou, Jean‐Michel Grellard, J.-M. Grellard, B. Clarisse, Bénédicte Clarisse, Idlir Licaj, I. Licaj, Djihane Ahmed-Lecheheb, D. Ahmed-Lecheheb, R. Fauvet, Patricia Pautier, P Pautier, Florence Joly, F Joly
Gynecologic Oncology · 2021 · vol. 163(3) , pp. 598–604 · doi:10.1016/j.ygyno.2021.10.001 · PMID:34649724 · W3205751342
Observational OA: bronze CC0
🔓 Open OA copy View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-08 ⓘ

This study investigated the prevalence and management of menopausal symptoms among epithelial ovarian cancer survivors.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

OBJECTIVE: We have previously shown that epithelial ovarian cancer (EOC) and its treatments have negative effects on long-term quality of life (QoL) and fatigue. The present multicenter study investigated the main menopausal symptoms and gynecological management of EOC survivors (EOCS). METHODS: 166 patients with relapse-free ≥3 years after the end of treatment attended a consultation with a gynecologist, including a questionnaire related to vasomotor symptoms (VMS) and sexuality, a clinical examination, a blood sample and an osteodensitometry. QoL, fatigue, insomnia and mood disorders were measured with validated questionnaires and correlated to VMS. VMS and QoL were assessed according to natural menopause (NM) or surgical menopause (SM). RESULTS: Mean age at the survey was 62 [21-83] years and stage III/IV (48%). Mean delay since the end of treatment was 6 years. Fifty-nine patients (36%) had SM. Half of patients reported VMS. Seventy-two percent of EOCS with SM had VMS compared to 41% with NM (P < .001). VMS were not associated with poor global QoL, fatigue, insomnia or mood disorders. Two-thirds of EOCS reported a decrease in libido. Patients with SM showed a greater decrease in libido than NM (P < .02). Fourteen percent of them had osteoporosis and 50% osteopenia. Among the 85 patients with VMS, 80 did not receive HRT after cancer treatment. At the time of the survey, only 7 (4%) patients were receiving hormone replacement therapy (HRT). CONCLUSIONS: VMS and sexual disorders are frequently reported by EOCS, particularly among patients with SM. Most EOCS with menopausal symptoms could benefit from HRT to improve these symptoms.

My notes (saved in your browser only)

MeSH descriptors

Cancer Survivors Carcinoma, Ovarian Epithelial Menopause Ovarian Neoplasms Adult Aged Aged, 80 and over Carcinoma, Ovarian Epithelial Carcinoma, Ovarian Epithelial Case-Control Studies Female Humans Menopause Middle Aged Ovarian Neoplasms Ovarian Neoplasms Quality of Life Sociodemographic Factors Vasomotor System Vasomotor System

Funding

funders
[{'doi': '10.13039/100004324', 'name': 'Astellas Pharma US', 'awards': []}, {'doi': '10.13039/501100003769', 'name': 'Eisai', 'awards': []}, {'doi': '10.13039/100004337', 'name': 'Roche', 'awards': []}, {'doi': '10.13039/501100004099', 'name': 'Ligue Contre le Cancer', 'awards': []}, {'doi': '10.13039/501100004431', 'name': 'Fondation de France', 'awards': []}, {'doi': '10.13039/100007054', 'name': 'Meso Scale Diagnostics', 'awards': []}, {'doi': '10.13039/100008349', 'name': 'Boehringer Ingelheim', 'awards': []}]

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.

References (71)

Source provenance

crossref
last seen: 2026-08-18T06:27:45.826669+00:00
openalex
last seen: 2026-05-11T06:08:11.709964+00:00
pubmed
last seen: 2026-10-08T21:32:46.934654+00:00
License: CC0 · commercial use OK